Amgen psoriasis candidate bests J&J's Stelara; FDA slams Sciecure insomnia drug sales materials;

> Amgen's ($AMGN) psoriasis drug brodalumab beat Johnson & Johnson's ($JNJ) Stelara at clearing patients' skin in a late-stage study, in the latest round of data for a soon-to-be-upended psoriasis market. Report

> The FDA's pharma marketing police slammed Sciecure Pharma for a lack of fair balance in a sales aid for its insomnia drug Doral. Report

> South Carolina-based Afaxys Pharmaceuticals says its emergency contraceptive, ella, is now available nationwide in the U.S.; the company is particularly focusing on public health providers, urgent centers, ERs and student health centers. Release

> The U.K. drugmaker BTG said it has finally launched its varicose vein treatment Varithena in the U.S., 18 years after it bought the technology. Release

And Finally... Servier is gambling up to $1B on Intarcia's late-stage drug-emitting diabetes device. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?